Mga Batayang Estadistika
| LEI | 549300VULMFHRONS7K42 |
| CIK | 1715925 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ImmunoPrecise Antibodies Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by chec |
|
| September 3, 2025 |
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision AUSTIN, TEXAS – ImmunoPrecise Antibodies Ltd. |
|
| September 2, 2025 |
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York AUSTIN, Texas, September 2nd, 2025 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025. Dr. Jennifer Bat |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by chec |
|
| August 27, 2025 |
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check m |
|
| August 6, 2025 |
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation AUSTIN, TEXAS – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. ( |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check m |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check m |
|
| August 1, 2025 |
ImmunoPrecise Antibodies Ltd. 3204-4464 Markham Street Victoria, BC, Canada V8Z 7X8 PH: +1 (250) 483-0308 Website: www.ipatherapeutics.com Email: [email protected] Date: August 1, 2025 To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: IMMUNOPRECISE ANTIBODIES LTD. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders fo |
|
| July 29, 2025 |
Exhibit 12.1 CERTIFICATION I, Jennifer Bath, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| July 29, 2025 |
Exhibit 4.7 GLOBAL GUARANTY AGREEMENT This Guaranty is made as of July 16, 2024 by ImmunoPrecise Antibodies (Canada), Ltd., British Columbia corporation (“ImmunoCanada”), ImmunoPrecise Antibodies (Europe) BV, a company incorporated in the Netherlands (“ImmunoDutch”), and BioStrand B.V., a company incorporated in Belgium ((“BioStrand”) and collectively with ImmunoCanada and ImmunoDutch, the “Guaran |
|
| July 29, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Scheffler, Interim Chief Financial Officer |
|
| July 29, 2025 |
Exhibit 4.5 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 16, 2024, is between IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation, with principal executive offices located at 3204-4464 Markham Street, Victoria, BC V8Z 7X8 (the “Company”), and each of the investors listed on the Schedule of Buyers attached as Schedule I hereto (indi |
|
| July 29, 2025 |
DISCLOSURE, CONFIDENTIALITY & TRADING POLICY DISCLOSURE, CONFIDENTIALITY & TRADING POLICY The Policy: This policy establishes procedures which are designed to: (i) permit the disclosure of information about IMMUNOPRECISE ANTIBODIES LTD. |
|
| July 29, 2025 |
As of the date of the Annual Report on Form 20-F (the “ Exhibit 2.1 As of the date of the Annual Report on Form 20-F (the “Annual Report”) of which this Exhibit 2.1 is a part, ImmunoPrecise Antibodies Ltd. (the “Company”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company’s common shares (the “Common Shares”). Description of Common Shares The following description of the Common S |
|
| July 29, 2025 |
Exhibit 16.1 July 29, 2025 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: ImmunoPrecise Antibodies Ltd. File No. 001-39530 Dear Sir or Madam: We have read Item 16F of Form 20-F of ImmunoPrecise Antibodies Ltd. dated July 29, 2025, and agree with the statements concerning our Firm contained therein. Very truly yours, /s/ GRANT THORNT |
|
| July 29, 2025 |
Exhibit 4.6 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 16, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collecti |
|
| July 29, 2025 |
Exhibit 12.2 CERTIFICATION I, Joseph Scheffler, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi |
|
| July 29, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated July 29, 2025, with respect to the consolidated financial statements included in this Annual Report on Form 20-F of ImmunoPrecise Antibodies Ltd., as filed with the United States Securities and Exchange Commission, for the year ended April 30, 2025. We also consent to the incorporation by referenc |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| July 29, 2025 |
ImmunoPrecise Antibodies (IPA) Reports Record Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA AUSTIN, Texas, July 29, 2025 – ImmunoPrecise Antibodies Ltd. |
|
| July 29, 2025 |
MATERIAL TRANSFER AND EVALUATION AGREEMENT THIS MATERIAL TRANSFER AND EVALUATION AGREEMENT (the “MTE Agreement,” and together with its Appendices, the “MTEA”) is made as of the date of the last signature below (the “Effective Date”) by and between Biotheus, Inc. |
|
| July 29, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jennifer Bath, Chief Executive Officer of the Com |
|
| July 29, 2025 |
Exhibit 97.1 IMMUNOPRECISE ANTIBODIES LTD. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of ImmunoPrecise Antibodies Ltd. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has |
|
| July 29, 2025 |
Exhibit 2.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWAR |
|
| July 24, 2025 |
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| July 21, 2025 |
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. |
|
| July 14, 2025 |
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| July 7, 2025 |
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| July 3, 2025 |
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data New benchmark confirms LENSai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| June 24, 2025 |
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ platform powered by patented HYFT® Technology Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential AUSTIN, Texas — ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| June 12, 2025 |
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies Breakthrough in AI-powered drug discovery validates HYFT®-driven peptide design, with broad potential across multiple therapeutic areas AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. |
|
| June 5, 2025 |
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mar |
|
| May 21, 2025 |
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts AUSTIN, Texas, May 21, 2025 - ImmunoPrecise Antibodies Ltd. |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check mark |
|
| May 12, 2025 |
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. |
|
| April 11, 2025 |
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma |
|
| April 10, 2025 |
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on One Investor Conference IPA to Present at The Benchmark Company’s Upcoming Discovery One-on One Investor Conference VICTORIA, British Columbia-(BUSINESS WIRE)-December 4, 2024-IPA (IMMUNOPRECISE ANTIBODIES LTD. |
|
| April 10, 2025 |
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period AUSTIN, Texas-(BUSINESS WIRE)-February 20, 2025-ImmunoPrecise Antibodies Ltd. |
|
| April 10, 2025 |
IPA to Present at The Microcap Conference 2025 IPA to Present at The Microcap Conference 2025 VICTORIA, British Columbia-(BUSINESS WIRE)-December 19, 2024-IPA (IMMUNOPRECISE ANTIBODIES LTD. |
|
| April 10, 2025 |
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy AUSTIN, Texas-(BUSINESS WIRE)-February 26, 2025-ImmunoPrecise Antibodies Ltd. |
|
| April 10, 2025 |
IPA Gives Update on the Status of its At-the-Market Program IPA Gives Update on the Status of its At-the-Market Program AUSTIN, Texas-April 9, 2025-ImmunoPrecise Antibodies Ltd. |
|
| March 28, 2025 |
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. |
|
| March 28, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2025. 2. No misrepresentati |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma |
|
| March 28, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, , Interim Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2025. 2. No misrepresentations: |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma |
|
| March 28, 2025 |
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2025 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company”, “ImmunoPrecise” or “IPA”) for the three and nine months end |
|
| March 28, 2025 |
Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2025 and 2024 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note January 31, 2025 $ April 30, 2024 $ ASSET |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma |
|
| March 13, 2025 |
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check ma |
|
| March 12, 2025 |
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 The Company to host an earnings conference call via webcast AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. |
|
| February 24, 2025 |
ImmunoPrecise Antibodies Announces Key Leadership Changes ImmunoPrecise Antibodies Announces Key Leadership Changes AUSTIN, TEXAS, – ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check |
|
| February 3, 2025 |
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check |
|
| January 27, 2025 |
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. Industrious 823 Congress Ave Suite 300 Austin, Texas 78701 (Address of principal executive office) Indicate by check |
|
| January 22, 2025 |
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment. |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch |
|
| January 17, 2025 |
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch |
|
| January 3, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company ImmunoPrecise Antibodies Ltd. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| December 23, 2024 |
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases VICTORIA, BRITISH COLUMBIA (CANADA), December 23, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| December 10, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended October 31, 2024. 2. No misrepresentatio |
|
| December 10, 2024 |
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2024 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company”, “ImmunoPrecise” or “IPA”) for the three and six months ended |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| December 10, 2024 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Kristin Taylor, certify that: 1. |
|
| December 10, 2024 |
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 Delivers $6. |
|
| December 10, 2024 |
Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended October 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note October 31, 2024 $ April 30, 2024 $ ASSETS |
|
| December 10, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended October 31, 2024. 2. No misrepresentati |
|
| December 10, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the "Company") on Form 20-F/A for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kristin Taylor, Chief Financial Officer of the Company, cert |
|
| December 10, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the "Company") on Form 20-F/A for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jennifer Bath, Chief Executive Officer of the Company, certi |
|
| December 10, 2024 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Jennifer Bath, certify that: 1. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| December 3, 2024 |
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on December 10, 2024 The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA (CANADA), December 3, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD. |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| November 18, 2024 |
Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") he |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| November 13, 2024 |
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments VICTORIA, BRITISH COLUMBIA (CANADA), November 13, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| November 4, 2024 |
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation VICTORIA, BRITISH COLUMBIA (CANADA), November 4, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch |
|
| October 28, 2024 |
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction VICTORIA, BRITISH COLUMBIA (CANADA), October 28, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X ( |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch |
|
| October 21, 2024 |
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 VICTORIA, BRITISH COLUMBIA (CANADA), October 21, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| October 11, 2024 |
To: All Canadian Securities Regulatory Authorities Date: October 10, 2024 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities AMENDED - SEE HIGHLIGHTED Subject: IMMUNOPRECISE ANTIBODIES LTD. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Record Date for Notice of Mee |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch |
|
| October 10, 2024 |
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design University of Washington’s Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics VICTORIA, BRITISH COLUMBIA (CANADA), October 10, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| October 2, 2024 |
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, BRITISH COLUMBIA (CANADA), ZHUHAI, (CHINA), October 2, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by ch |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by |
|
| September 26, 2024 |
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments Rabbit B Cell Select® Drives Clinical Breakthroughs in Cancer Treatment VICTORIA, BRITISH COLUMBIA (CANADA), September 26, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| September 23, 2024 |
To: All Canadian Securities Regulatory Authorities Date: September 20, 2024 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: IMMUNOPRECISE ANTIBODIES LTD. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice of Meeting : Octob |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X |
|
| September 18, 2024 |
IMMUNOPRECISE ANTIBODIES LTD. 3204 - 4464 Markham Street Victoria, British Columbia V8Z 7X8 September 17, 2024 Form 51-102F6 STATEMENT OF EXECUTIVE COMPENSATION (for the financial year ended April 30, 2024) This Statement of Executive Compensation is filed by ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) pursuant to National Instrument 51‐102 – Continuous Disclosure Obligations under Cana |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by |
|
| September 16, 2024 |
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2024 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (the "Company”, “ImmunoPrecise” or “IPA”) for the three months ended July 31, 2024, tog |
|
| September 16, 2024 |
Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note July 31, 2024 $ April 30, 2024 $ ASSETS Current asset |
|
| September 16, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended July, 31, 2024. 2. No misrepresentations |
|
| September 16, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended July, 31, 2024. 2. No misrepresentation |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| September 16, 2024 |
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 Achieves $5. |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by |
|
| September 10, 2024 |
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 The Company to host an earnings conference call via webcast. |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by che |
|
| August 26, 2024 |
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements VICTORIA, BRITISH COLUMBIA (CANADA), August 23, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by che |
|
| August 26, 2024 |
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York VICTORIA, BRITISH COLUMBIA (CANADA), August 26, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), is pleased to announce that it will be attending H.C. Wainwright's 26th Annual Global Investment Conference (the "Global Investment Conference"). The Company's m |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by che |
|
| August 19, 2024 |
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology Engineering antibodies in silico using LENSai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA's vision to make groundbreaking and safer therapeutics instantly accessible and affordable. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNOPRECISE ANTIBODIES LTD. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) British Columbia (Province or Other Jurisdiction of Incorporation or Organization) Not Applicable (I.R.S. Employer |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) ImmunoPrecise Antibodies Ltd. |
|
| July 30, 2024 |
ImmunoPrecise Antibodies Ltd. Up to U.S.$8,800,000 Common Shares AMENDMENT NO. 1 DATED JULY 29, 2024 to Prospectus Supplement dated February 23, 2024 (To Prospectus dated July 14, 2023) Filed Pursuant to Rule 424(b)(5) Registration No. 333-273197 ImmunoPrecise Antibodies Ltd. Up to U.S.$8,800,000 Common Shares This Amendment No. 1 to Prospectus Supplement (this "Amendment") amends our prospectus supplement dated February 23, 2024 (the "Prospectus Supplement). T |
|
| July 29, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kristin Taylor, Chief Financial Officer of the Co |
|
| July 29, 2024 |
Exhibit 4.7 GLOBAL GUARANTY AGREEMENT This Guaranty is made as of July 16, 2024 by ImmunoPrecise Antibodies (Canada), Ltd., British Columbia corporation (“ImmunoCanada”), ImmunoPrecise Antibodies (Europe) BV, a company incorporated in the Netherlands (“ImmunoDutch”), and BioStrand B.V., a company incorporated in Belgium ((“BioStrand”) and collectively with ImmunoCanada and ImmunoDutch, the “Guaran |
|
| July 29, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of ImmunoPrecise Antibodies Ltd. (the “Company”) on Form 20-F for the period ended April 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jennifer Bath, Chief Executive Officer of the Com |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| July 29, 2024 |
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 Achieves Record $24. |
|
| July 29, 2024 |
As of the date of the Annual Report on Form 20-F (the “ Exhibit 2.1 As of the date of the Annual Report on Form 20-F (the “Annual Report”) of which this Exhibit 2.1 is a part, ImmunoPrecise Antibodies Ltd. (the “Company”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company’s common shares (the “Common Shares”). Description of Common Shares The following description of the Common S |
|
| July 29, 2024 |
Exhibit 15.1 We have issued our report dated July 29, 2024, with respect to the consolidated financial statements included in this Annual Report on Form 20-F of ImmunoPrecise Antibodies Ltd. (the “Company”) for the year ended April 30, 2024, as filed with the United States Securities and Exchange Commission. We consent to the incorporation by reference of our report into the Registration Statement |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check |
|
| July 29, 2024 |
IMMUNOPRECISE ANTIBODIES LTD. Convertible Debenture Exhibit 2.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THOSE SECURITIES INTO WHICH THEY ARE CONVERTIBLE HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWAR |
|
| July 29, 2024 |
IMMUNOPRECISE ANTIBODIES LTD. INCENTIVE COMPENSATION RECOVERY POLICY Exhibit 97.1 IMMUNOPRECISE ANTIBODIES LTD. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of ImmunoPrecise Antibodies Ltd. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has |
|
| July 29, 2024 |
Exhibit 4.5 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 16, 2024, is between IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation, with principal executive offices located at 3204-4464 Markham Street, Victoria, BC V8Z 7X8 (the “Company”), and each of the investors listed on the Schedule of Buyers attached as Schedule I hereto (indi |
|
| July 29, 2024 |
Exhibit 4.6 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 16, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and IMMUNOPRECISE ANTIBODIES LTD., a British Columbia corporation (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collecti |
|
| July 29, 2024 |
Exhibit 12.1 CERTIFICATION I, Jennifer Bath, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| July 29, 2024 |
Exhibit 12.2 CERTIFICATION I, Kristin Taylor, certify that: 1. I have reviewed this annual report on Form 20-F of ImmunoPrecise Antibodies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| July 24, 2024 |
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year End 2024 The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA, July 23, 2024 - ImmunoPrecise Antibodies Ltd. |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check |
|
| July 17, 2024 |
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3. |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| July 15, 2024 |
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA (CANADA), July 15, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD. |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check |
|
| June 27, 2024 |
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer VICTORIA, BRITISH COLUMBIA (CANADA), June 27, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| June 25, 2024 |
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™ VICTORIA, BRITISH COLUMBIA (CANADA), June 25, 2024 – ImmunoPrecise Antibodies Ltd. |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by check |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| June 12, 2024 |
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology VICTORIA, British Columbia, June 12, 2024 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with the pre |
|
| June 10, 2024 |
BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery -BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| June 4, 2024 |
IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland VICTORIA, BRITISH COLUMBIA (CANADA), June 03, 2024 - IPA (IMMUNOPRECISE ANTIBODIES LTD. |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| March 28, 2024 |
InterSystems and IPA's Subsidiary BioStrand Unveil the Innovative Integration of Vector Search with LENSai for AI- Driven Healthcare Applications VICTORIA, BRITISH COLUMBIA (CANADA), March 28, 2024 - IPA (IMMUNOPRECISE ANTIBODIES LTD. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add |
|
| March 20, 2024 |
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPA's diversity- and data-driven drug development and to enrich LENSai™. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (A |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (A |
|
| March 14, 2024 |
Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note January 31, 2024 $ April 30, 2023 $ ASSET |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by chec |
|
| March 14, 2024 |
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company” or “IPA”) for the three and nine months ended January 31, 20 |
|
| March 14, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2024. 2. No misrepresentat |
|
| March 14, 2024 |
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* IPA reports a fourth consecutive quarter of increased revenue. |
|
| March 14, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended January, 31, 2024. 2. No misrepresentati |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant's name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Addres |
|
| March 7, 2024 |
IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida VICTORIA, BRITISH COLUMBIA (CANADA), March 7, 2024 - IPA (IMMUNOPRECISE ANTIBODIES LTD. |
|
| February 23, 2024 |
ImmunoPrecise Antibodies Ltd. Up to U.S.$60,000,000 Common Shares PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 |
|
| February 23, 2024 |
SALES AGREEMENT February 23, 2024 CLEAR STREET LLC 4 World Trade Center, Floor 45 New York, New York 10007 Ladies and Gentlemen: ImmunoPrecise Antibodies Ltd. |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by |
|
| February 15, 2024 |
Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended October 31, 2023 and 2022 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note October 31, 2023 $ April 30, 2023 $ ASSETS |
|
| January 10, 2024 |
IPA / ImmunoPrecise Antibodies Ltd. / Charmquark TWEE - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Immunoprecise Antibodies Ltd. |
|
| January 10, 2024 |
IPA / ImmunoPrecise Antibodies Ltd. / Charmquark TWEE - SCHEDULE 13G AMENDMENT Passive Investment SC 13G/A 1 sc13ga.htm SCHEDULE 13G AMENDMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G AMENDMENT NO. 1 INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Immunoprecise Antibodies Ltd. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 45257F200 (CUSIP Number) December 31, 2022 (Date of Event Which Re |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| December 14, 2023 |
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* Exhibit 99.1 IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* VICTORIA, British Columbia-(BUSINESS WIRE)-December 14, 2023-IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fi |
|
| December 14, 2023 |
Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended October 31, 2023 and 2022 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note October 31, 2023 $ April 30, 2023 $ ASSETS |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by c |
|
| December 14, 2023 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company ImmunoPrecise Antibodies Ltd. |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add |
|
| December 14, 2023 |
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2023 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company”, “ImmunoPrecise” or “IPA”) for the three and six months ended |
|
| December 14, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of ImmunoPrecise Antibodies, Ltd. (the "issuer") for the interim period ended October, 31, 2023. 2. No misrepresentati |
|
| December 14, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of ImmunoPrecise Antibodies, Ltd. (the "issuer") for the interim period ended October, 31, 2023. 2. No misrepresentat |
|
| December 8, 2023 |
IPA Announces Closing of $1.265 Million Public Offering of Common Shares Exhibit 99.1 IPA Announces Closing of $1.265 Million Public Offering of Common Shares VICTORIA, British Columbia-(BUSINESS WIRE)-December 8, 2023-ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced the closing of its $1.265 million underwritten public offering of 1,265,000 common shares, including 165,000 common shares issued pursuant to the ful |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add |
|
| December 7, 2023 |
ImmunoPrecise Antibodies Ltd. 1,100,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-273197 PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) ImmunoPrecise Antibodies Ltd. 1,100,000 Common Shares ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA" or "we" or "our" or "us") is offering ("Offering") up to 1,100,000 common shares of the Company, without par value (the "Common Shares"). Our Common Shares are listed and tr |
|
| December 6, 2023 |
UNDERWRITING AGREEMENT between IMMUNOPRECISE ANTIBODIES LTD. and THE BENCHMARK COMPANY LLC as Representative of the Several Underwriters IMMUNOPRECISE ANTIBODIES LTD. UNDERWRITING AGREEMENT New York, New York December 5, 2023 The Benchmark Company LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 150 E. 58th Street, 17th Floor New York, NY 10155 Ladies and Gentl |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 |
|
| December 6, 2023 |
IPA Announces Proposed Public Offering of Common Shares Exhibit 99.1 IPA Announces Proposed Public Offering of Common Shares VICTORIA, British Columbia-(BUSINESS WIRE)-December 5, 2023-ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced that it intends to offer and sell common shares in an underwritten public offering. All of the common shares in the underwritten public offering are to be sold by the |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add |
|
| December 6, 2023 |
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares Exhibit 99.1 IPA Announces Pricing of $1.1 Million Public Offering of Common Shares VICTORIA, British Columbia-(BUSINESS WIRE)-December 6, 2023-ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) today announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share. All common shares in the u |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add |
|
| December 5, 2023 |
SUBJECT TO COMPLETION, DATED DECEMBER 5, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-273197 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell and are |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add |
|
| November 27, 2023 |
Exhibit 99.1 ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call VICTORIA, British Columbia-(BUSINESS WIRE)-November 27, 2023-ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board o |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 |
|
| November 16, 2023 |
Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") he |
|
| November 13, 2023 |
Exhibit 99.1 BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research VICTORIA, British Columbia-(BUSINESS WIRE)-November 13, 2023-ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its su |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Add |
|
| October 25, 2023 |
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™ Exhibit 99.1 IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™ BioStrand Unveils Groundbreaking Retrieval Augmented Generation (RAG)-Based LLM Platform Integrated with Patented HYFT Technology BioStrand's Work Exemplifies the IPA Family's Investment in Advanced AI, Aiding Partners in Developing New Biologics for Previously Undruggable Targets VICTORIA, British Columbia-(BUSINESS WIRE)-Oct |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Addr |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Addr |
|
| October 23, 2023 |
IPA Provides Update on Growth Strategy and Recent Share Price Movement Exhibit 99.1 IPA Provides Update on Growth Strategy and Recent Share Price Movement VICTORIA, British Columbia-(BUSINESS WIRE)-October 23, 2023-ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology company wishes to provide an update on its overall growth strategy, particularly in light of recent market developments. IPA remains c |
|
| October 20, 2023 |
IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 9, 2023 AND INFORMATION CIRCULAR October 16, 2023 - 2 - IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street, Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting ( |
|
| October 20, 2023 |
IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street, Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the "Meeting") of the shareholders of ImmunoPrecise Antibodies Ltd. (the "Company") will be held via live webcast at https://meetnow.global/MXV4AUH on Thursday, November 9, 2023, at 10 a.m. (PST) for the followi |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 |
|
| October 20, 2023 |
OFFICER’S CERTIFICATE TO: Alberta Securities Commission British Columbia Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Manitoba Securities Commission Ontario Securities Commission Financial and Consumer Services Commission of New Brunswick Nova Scotia Securities Commission The Office of the Superintendent Securities, Consumer, Corporate and Insurance Services Division, Office of the Attorney General of Prince Edward Island Office of the Superintendent of Securities, Service Newfoundland & Labrador RE: Abridging Time Pursuant to National Instrument 54-101 – Communication With Beneficial Owners of Securities of a Reporting Issuer ("NI 54-101") Pursuant to subsection 2. |
|
| October 20, 2023 | ||
| September 26, 2023 |
Form 51-102F3 MATERIAL CHANGE REPORT Form 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company IMMUNOPRECISE ANTIBODIES LTD. |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X |
|
| September 25, 2023 |
To: Alberta Securities Commission Date: September 22, 2023 3204-4464 Markham St., Victoria, British Columbia, V8Z 7X8, Canada To: Alberta Securities Commission British Columbia Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Manitoba Securities Commission Ontario Securities Commission Financial and Consumer Services Commission of New Brunswick Nova Scotia Securities Commission The Office of the Super |
|
| September 19, 2023 |
ImmunoPrecise Antibodies Announces CFO Transition Exhibit 99.1 ImmunoPrecise Antibodies Announces CFO Transition Brad McConn to Step Down Later This Month Kristin Taylor, MBA, CPA, Named Interim CFO VICTORIA, British Columbia-(BUSINESS WIRE)-September 19, 2023-IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effective September 29, 2023. IPA has n |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X |
|
| September 18, 2023 |
IMMUNOPRECISE ANTIBODIES LTD. 3204 - 4464 Markham Street Victoria, British Columbia V8Z 7X8 September 15, 2023 Form 51-102F6 STATEMENT OF EXECUTIVE COMPENSATION (for the financial year ended April 30, 2023) This Statement of Executive Compensation is filed by ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") pursuant to Section 11.6 of National Instrument 51‐102 - Continuous Disclosure Obliga |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive office) Indicate by |
|
| September 14, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Brad McConn, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended July, 31, 2023. 2. No misrepresentations: |
|
| September 14, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ImmunoPrecise Antibodies, Ltd. (the “issuer”) for the interim period ended July, 31, 2023. 2. No misrepresentations |
|
| September 14, 2023 |
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2023 Exhibit 99.1 The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the Company”, “ImmunoPrecise” or “IPA”) for the three months ended July 31, 2023, tog |
|
| September 14, 2023 |
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 Exhibit 99.1 IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 Company recorded record quarterly revenue, an increase of 21.3% compared to the same quarter last year. Significantly higher net income before taxes when compared to Q1 of last year, a difference of approximately $6 million dollars, another positive back-to-back quarter trend. VICTORIA, Bri |
|
| September 14, 2023 |
Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2023 and 2022 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note July 31, 2023 $ April 30, 2023 $ ASSETS Current asset |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X |
|
| September 13, 2023 |
Form 51-102F3 MATERIAL CHANGE REPORT Form 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company IMMUNOPRECISE ANTIBODIES LTD. |
|
| September 8, 2023 |
Exhibit 99.1 IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023 The Company to host an earnings conference call via webcast VICTORIA, British Columbia-(BUSINESS WIRE)-September 8, 2023-IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today anno |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Ad |
|
| September 5, 2023 |
IPA Announces Board Refreshment Exhibit 99.1 IPA Announces Board Refreshment IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors VICTORIA, British Columbia-(BUSINESS WIRE)-September 5, 2023-IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, |
|
| August 16, 2023 |
OPEN MARKET SALE AGREEMENTSM August 15, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ImmunoPrecise Antibodies Ltd. |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 ( |
|
| August 16, 2023 |
Up to U.S.$60,000,000 Common Shares PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022. Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7 |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Addre |
|
| August 9, 2023 |
Exhibit 99.1 IPA Responds to 13D Filing IPA responds to 13D Filing by Ingalls & Snyder, LLC VICTORIA, British Columbia-(BUSINESS WIRE)-August 9, 2023-IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the following statement in response to the Schedule 13D filing made on July 7, 2023 by Ingalls & Snyd |
|
| July 14, 2023 |
Exhibit 99.1 ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research VICTORIA, British Columbia-(BUSINESS WIRE)-July 14, 2023-ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invitation to investors and other interested parties to participate in |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Translation of registrant’s name into English) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address |
